Filing Flows › Ginkgo Bioworks Holdings (DNA) › Q2 2026
Ginkgo Bioworks Holdings (DNA) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Ginkgo Bioworks Holdings (DNA) reported revenue of $20.2M for the second quarter 2026 (Q2 2026), -48% from a year earlier and +4% from the quarter before. Operating margin was -290.5%, net loss $46.7M (231.7% of revenue).
Ginkgo Bioworks Holdings, Q2 2026: revenue $20.2M (-48% year over year), operating margin -290.5%, net loss $46.7M, operating cash flow −$44.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.2M | +4% | -48% |
| Operating profit | −$58.5M | — | — |
| Net earnings | −$46.7M | — | — |
| Operating cash flow | −$44.3M | — | — |
What changed
Revenue was $20.2M in Q2 2026, down 48% year over year and up 4% from the previous quarter.
Operating costs exceeded revenue by $58.5M, an operating margin of -290.5%. Total costs fell 19% while revenue fell 48%. The quarter ended with a net loss of $46.7M, narrower than the previous quarter's $82.6M loss. Non-operating items added $12.0M, -26% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$44.3M. Non-cash charges added back $12.3M of depreciation and amortization and $7.6M of share-based compensation. Working capital and other items used $17.5M. Capital expenditures of $2.6M exceeded it, leaving free cash flow of −$46.9M.
Questions
What was Ginkgo Bioworks Holdings' revenue in the second quarter 2026?
Ginkgo Bioworks Holdings (DNA) reported revenue of $20.2M for the second quarter 2026 (Q2 2026), -48% from a year earlier and +4% from the quarter before.
Was Ginkgo Bioworks Holdings profitable in the second quarter 2026?
Operating loss was $58.5M (-290.5% of revenue) and net loss $46.7M.